Skip to content

Roivant Sciences Ltd Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 9, 2026 results vs estimates

Roivant Sciences Ltd · E.ROIV.NASDAQ · United States
Use symbol E.ROIV.NASDAQ in our API & Excel add-in to retrieve this data ↓
37.52
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 36.51%

Roivant Sciences Ltd Forecast

Roivant Sciences Ltd short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 36.5% a year, a typical one-standard-deviation range is 35.59–39.45 over a week, 33.57–41.47 over a month and 23.82–51.22 over a year. (Signals as of 1 Nov 2026.)

Roivant Sciences Ltd Price Chart

MacroFinance.ai

Roivant Sciences Ltd Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Roivant Sciences Ltd
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Roivant Sciences Ltd
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Roivant Sciences Ltd
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Roivant Sciences Ltd
P/S
660.09x
Mid-range vs own history
QoQ −81.0%
YoY −2.5%
now 660.0857660.09 low3,906 high
ⓘP/S As of 22 Nov 2026.See Roivant Sciences Ltd returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Roivant Sciences Ltd
P/B
6.75x
Mid-range vs own history
QoQ +9.1%
YoY +113.7%
now 6.74523.25 low7.11 high
ⓘP/B As of 22 Nov 2026.See Roivant Sciences Ltd returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Roivant Sciences Ltd
EV/Sales
560.26x
Mid-range vs own history
QoQ −81.2%
YoY +20.1%
now 560.2606486.18 low3,410 high
ⓘEV/Sales As of 22 Nov 2026.See Roivant Sciences Ltd returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Roivant Sciences Ltd
FCF Yield
-0.2%
Strong vs own history
QoQ −95.0%
YoY −97.2%
now -0.1593-5.54 low-0.15 high
ⓘFCF Yield As of 22 Nov 2026.See Roivant Sciences Ltd returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Roivant Sciences Ltd
Earnings Yield
-1.3%
Mid-range vs own history
QoQ +24.8%
YoY −53.2%
now -1.2698-4.5 low-0.9 high
ⓘEarnings Yield As of 22 Nov 2026.See Roivant Sciences Ltd returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Roivant Sciences Ltd
Market Cap
$27.1B
Highest in 5 years
QoQ +3.6%
YoY +97.0%
now 27117.6414,171 low29,422 high
ⓘMarket Cap As of 22 Nov 2026.See Roivant Sciences Ltd returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Roivant Sciences Ltd
Net Debt
-$4.1B
Mid-range vs own history
QoQ +9.8%
YoY −4.3%
now -4101.016-4,323 low-3,735 high
ⓘNet Debt As of 22 Nov 2026.See Roivant Sciences Ltd returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Roivant Sciences Ltd
Current Ratio
15.56x
Mid-range vs own history
QoQ −6.9%
YoY −53.8%
now 15.560515.56 low33.7 high
ⓘCurrent Ratio As of 22 Nov 2026.See Roivant Sciences Ltd returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Roivant Sciences Ltd
Quick Ratio
15.56x
Mid-range vs own history
QoQ −6.9%
YoY −53.8%
now 15.560515.56 low33.7 high
ⓘQuick Ratio As of 22 Nov 2026.See Roivant Sciences Ltd returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Roivant Sciences Ltd
Debt / Equity
0.03x
Mid-range vs own history
QoQ +4.6%
YoY +17.0%
now 0.02650.02 low0.05 high
ⓘDebt / Equity As of 22 Nov 2026.See Roivant Sciences Ltd returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Roivant Sciences Ltd
Piotroski F-Score
2
Mid-range vs own history
QoQ +100.0%
YoY −33.3%
now 21 low3 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Roivant Sciences Ltd returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Roivant Sciences Ltd
Altman Z-Score
43.27
Strong vs own history
QoQ +4.5%
YoY +33.2%
now 43.27233.42 low49.93 high
ⓘAltman Z-Score As of 22 Nov 2026.See Roivant Sciences Ltd returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  17 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  15 members-only factors: Sloan Accruals, Cash-Earnings Gap, Gross Margin Index, Asset Quality Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Roivant Sciences Ltd, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Roivant Sciences Ltd fundamentals: income statement, balance sheet & cash flow

Roivant Sciences Ltd reported revenue of $8.3m and net income of -$299.8m in FY2026, the year ended 31 March 2026 — revenue down 71.6% and net income down 74.3% on the prior year. Free cash flow was -$758.6m. These figures are as reported in the filings, not restated: 8 fiscal years and 27 quarters of history, back to March 2019. 119 FINRA short-interest settlements are published alongside them, back to October 2021.

Revenue (FY2026)
$8.3m
-71.6%
Net income
-$299.8m
-74.3%
Gross margin
84.44%
Free cash flow
-$758.6m
+10.1%
Net debt
-$1.31bn
Shares short (30 Oct 2026)
45.51m
6.07 days to cover
Roivant Sciences Ltd income statement, annual, as reported · USD millions unless stated
USD millionsFY2026FY2025FY2024FY2023FY2022
Period end31 Mar 202631 Mar 202531 Mar 202431 Mar 202331 Mar 2022
Revenue8.329.132.731.555.3
Cost of revenue1.30.91.63.09.0
Gross profit7.028.131.128.546.3
Research & development681.8550.4439.9454.1483.0
Selling, general & admin.————775.0
Operating income-515.1-1,003.34,497.0-906.8-1,211.7
EBITDA-261.2-667.54,624.7-838.2-910.8
Interest expense——34.828.07.0
Pre-tax income-264.6-681.64,567.9-885.0-923.7
Income tax133.348.221.54.10.4
Net income-299.8-172.04,348.9-1,009.0-845.3

Download Roivant Sciences Ltd fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.ROIV.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks the full history, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Roivant Sciences Ltd

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Roivant Sciences Ltd Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Roivant Sciences Ltd; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Roivant Sciences Ltd’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Roivant Sciences Ltd behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Roivant Sciences Ltd (United States)

Roivant Sciences Ltd is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Roivant Sciences Ltd?
Roivant Sciences Ltd is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Roivant Sciences Ltd price?
The latest close is 37.52 (1 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Roivant Sciences Ltd in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Roivant Sciences Ltd?
20-day realised volatility is 36.5% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 10.5% over a month and 5.1% over a week.
What factors affect Roivant Sciences Ltd?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Roivant Sciences Ltd, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Roivant Sciences Ltd?
58 backtested tactical asset allocation strategies trade Roivant Sciences Ltd through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Roivant Sciences Ltd returns analysed?
The Statistical Distribution of Returns section shows the distribution of Roivant Sciences Ltd daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Roivant Sciences Ltd historical data?
In the Free historical data section of this page: the last 10 years of Roivant Sciences Ltd daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Roivant Sciences Ltd historical data (last 10 years)

Browse or instantly download the last 10 years of Roivant Sciences Ltd daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.ROIV.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2038.655
2026-11-1938.96
2026-11-1838.73
2026-11-1738.71
2026-11-1638.61
2026-11-1339.53
2026-11-1239.99
2026-11-1141.85
2026-11-1041.19
2026-11-0940.67
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.